C12N 9/78
Acting on carbon to nitrogen bonds other than peptide bonds
Official title: acting on carbon to nitrogen bonds other than peptide bonds (3.5)
C12N9/78 (Acting on carbon to nitrogen bonds other than peptide bonds) appears on 1,647 US grants and 2,334 published applications in this corpus.
Search patents in C12N- Granted patents
- 1,647
- Published applications
- 2,334
- Assignees
- 1,079
- Inventors
- 5,071
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 5 | 0 |
| 1978 | 4 | 0 |
| 1979 | 2 | 0 |
| 1980 | 3 | 0 |
| 1981 | 7 | 0 |
| 1982 | 5 | 0 |
| 1983 | 6 | 0 |
| 1984 | 9 | 0 |
| 1985 | 5 | 0 |
| 1986 | 4 | 0 |
| 1987 | 8 | 0 |
| 1988 | 4 | 0 |
| 1989 | 12 | 0 |
| 1990 | 14 | 0 |
| 1991 | 16 | 0 |
| 1992 | 15 | 0 |
| 1993 | 24 | 0 |
| 1994 | 27 | 0 |
| 1995 | 12 | 0 |
| 1996 | 20 | 0 |
| 1997 | 29 | 0 |
| 1998 | 55 | 0 |
| 1999 | 51 | 0 |
| 2000 | 50 | 0 |
| 2001 | 67 | 5 |
| 2002 | 58 | 52 |
| 2003 | 44 | 85 |
| 2004 | 34 | 75 |
| 2005 | 29 | 59 |
| 2006 | 33 | 51 |
| 2007 | 33 | 46 |
| 2008 | 38 | 48 |
| 2009 | 19 | 70 |
| 2010 | 43 | 67 |
| 2011 | 50 | 56 |
| 2012 | 34 | 61 |
| 2013 | 32 | 58 |
| 2014 | 45 | 43 |
| 2015 | 40 | 55 |
| 2016 | 35 | 88 |
| 2017 | 43 | 75 |
| 2018 | 42 | 84 |
| 2019 | 52 | 85 |
| 2020 | 64 | 123 |
| 2021 | 59 | 126 |
| 2022 | 63 | 178 |
| 2023 | 70 | 165 |
| 2024 | 68 | 196 |
| 2025 | 96 | 204 |
| 2026 | 67 | 179 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Method for modulating RNA splicing by inducing base mutation at splice site or base substitution in polypyrimidine region6 Oct 2026US 12,753,420 B2Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences
- DCAS13-mediated therapeutic RNA base editing for in vivo gene therapy29 Sep 2026US 12,746,295 B2University of Massachusetts
- Adenine deaminases and compositions, systems, and methods thereof29 Sep 2026US 12,747,436 B2Profluent Bio Inc.
- Compositions comprising a CAS12I polypeptide and uses thereof29 Sep 2026US 12,747,457 B2Arbor Biotechnologies, Inc.
- Histone deacetylase inhibitors for use in immunotherapy22 Sep 2026US 12,740,986 B2Viracta Subsidiary, Inc.
- Base editing approaches to treat abca4-associated stargardt disease8 Oct 2026US 2026/0306670 A1Massachusetts Eye and Ear Infirmary
- Cas-embedded Cytidine Deaminase Ribonucleoprotein Complexes having Improved Base Editing Specificity and Efficiency8 Oct 2026US 2026/0308553 A1University of Massachusetts
- Adenine base editors with reduced off-target effects8 Oct 2026US 2026/0308561 A1President and Fellows of Harvard College
- New high expression and high activity n-glycosidases, methods of production and applications thereof8 Oct 2026US 2026/0308562 A1Centre National de la Recherche Scientifique (CNRS)
- System, Kit, and Method for Continuous Directed Evolution8 Oct 2026US 2026/0308569 A1The Board of Trustees of the University of Illinois
Most cited
By later US patents
- Delivery of exogenous DNA sequences in a mammal1,218US 5,580,859 AVical Incorporated · 1996
- Induction of a protective immune response in a mammal by injecting a DNA sequence885US 5,589,466 AVical Incorporated · 1996
- Methods for in vitro recombination882US 5,605,793 AAffymax Technologies N.V. · 1997
- Methods and compositions for cellular and metabolic engineering844US 5,837,458 AMaxygen, Inc. · 1998
- DNA mutagenesis by random fragmentation and reassembly791US 5,830,721 AAffymax Technologies N.V. · 1998